Pharvaris (PHVS) Update / Briefing Transcript

Summary of Farvaris Conference Call Company and Industry Overview - Company: Farvaris - Industry: Pharmaceutical, specifically focusing on treatments for bradykinin mediated angioedema (HAE) Key Points and Arguments 1. Introduction of Ducryptoban: Farvaris is developing ducryptoban, an oral therapy aimed at treating bradykinin mediated angioedema, including types beyond hereditary angioedema (HAE) types one and two [2][4][16] 2. Unmet Medical Needs: There is a significant unmet need for effective treatments for patients with bradykinin mediated angioedema, particularly those with normal C1 inhibitor levels, which represent an additional 15-25% of patients [17][36] 3. Clinical Trials: Two pivotal Phase III studies are ongoing to evaluate the efficacy and safety of ducryptoban for both prophylactic and on-demand treatment of HAE attacks [17][33] 4. Biomarker Development: A novel biomarker assay has been developed to identify individuals with bradykinin mediated angioedema, which could enhance diagnosis and treatment management [24][31] 5. Current Treatment Landscape: The current treatment options for bradykinin mediated angioedema are limited, with many patients relying on off-label treatments that do not adequately address their needs [36][45] Additional Important Content 1. Types of Angioedema: The call discussed various types of bradykinin mediated angioedema, including hereditary angioedema due to C1 inhibitor deficiency and acquired forms, emphasizing the need for accurate diagnosis and tailored treatment approaches [8][10][12] 2. Challenges in Diagnosis: Diagnosing bradykinin mediated angioedema, especially in patients with normal C1 inhibitor levels, is challenging due to the lack of measurable biomarkers [11][23] 3. Regulatory Support: Farvaris has received orphan drug designation from both US and EU regulatory authorities for ducryptoban, highlighting the potential for this treatment to address significant unmet medical needs [45] 4. Community Engagement: Farvaris is collaborating with patient organizations and experts to better understand the needs of those living with bradykinin mediated angioedema [16][36] 5. Future Directions: The company aims to expand treatment options for patients with bradykinin mediated angioedema beyond HAE types one and two, with ongoing studies expected to provide critical data for regulatory filings [45][44] This summary encapsulates the key discussions and insights from the Farvaris conference call, focusing on the company's initiatives and the broader context of bradykinin mediated angioedema treatment.